The Search for an HIV Vaccine: The Past, The Present and The Promise

Dec 14, 2017
By IQVIA

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/promise

You’ve delivered great progress in the treatment and prevention of HIV in the three decades since its discovery, and slowed the rate of new infections in many countries. However, work continues in developing a safe and effective vaccine, a goal we’ve yet to reach due to the unique nature of the HIV-1 virus and the complex human dimensions of the infection, such as same-sex and mother-to-child transmission, the breadth of cultures involved and hard-to-treat patients. And while the use of PrEP and treatment as prevention has greatly reduced rates of transmission, its use has also had an impact on vaccine study design. You require new data, new insights and new expertise to deliver an effective HIV-1 vaccine, an indispensable component in the race to end HIV world-wide.

Join this webinar for a discussion of the progress you’ve made, the lessons learned, and the challenging road ahead in developing an HIV vaccine. We’ll summarize recent advances in the immunopathology of HIV, encouraging new developments in vaccine research, the very limited status of pediatric studies, and why your work to develop a vaccine is more critical than ever to ending the pandemic.

 

Speakers:

Paul Turner, Sr. Medical Director, Infectious Diseases and Vaccines, IQVIA

Nuria Martinez-Alier, Sr. Medical Director, Infectious Diseases and Vaccines, IQVIA

 

Date and Time:

Live: Thursday, Dec. 14, 2017 | 11 am EST

After the final airing of the webcast on Dec. 14, 2017 it will be available on demand until Dec. 14, 2018. 

Sponsor: IQVIA

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/promise

native1_300x100
lorem ipsum